JPRN-UMIN000008182已完成1 期
A phase I study of bevacizumab and amrubicin after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancer - Phase I study of bevacizumab and amrubicin
ational Hospital Organization Kyushu Medical Center Department of Respiratory Medicine0 个研究点目标入组 15 人开始时间: 2012年6月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Squamous cell carcinoma 2)Discontinued bevacizumab due to its toxicity during a first line treatment 3)Serious infections/with fever 4)Serious clinical problems 5)Interstitial pneumonia/lung fibrosis on chest X-ray 6)History or complication of hemoptysis with 2.5ml per time or more 7)Continuous bloody phlegm more than 1 week or complication of bloody phlegm treated with continuous oral hemostatic agent. History or complication of bloody phlegm treated with infusional hemostatic agent. 8)Tumor cavitation 9)Uncontrollable hypertension 10)History of GI perforation 11)Previous treatment with amrubicin 12)Massive pericardial, pleural effusion, ascites 13)Active concomitant malignancy 14)Symptomatic brain metastasis 15)Previous drug allergy 16)Those judged to be not suitable by the attending physician
研究者
相似试验
招募中
不适用
Phase 2 study of amrubicin plus bevacizumab in patients with previously treated advanced non-sq NSCLCon small cell lung cancerJPRN-UMIN000013350Gunma University Graduate School of Medicine40
进行中（未招募）
不适用
Phase I-II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Erlotinib (EGFR TKI) plus Oxaliplatin and Capecitabine (XELOX) in Patients with Metastatic Colorectal Cancer: XELOX-TARAV study - XELOX-TARAVEUCTR2005-005548-21-ITCONSORZIO ONCOTECH
招募中
不适用
Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.Breast CancerJPRN-UMIN000010466Kansai medical university23
进行中（未招募）
不适用
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. - Bevacizumab + Docetaxel-Capecitabina MammellaPatients with advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2006-003929-83-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA
已完成
2 期
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapymetastatic colorectal cancerJPRN-UMIN000002407Sapporo City General Hospital20